Loading clinical trials...
Loading clinical trials...
An Open Label International Multi-Center Phase 2 Activity And Safety Study Of SU011248 In Patients With Advanced / Metastatic Gastric Cancer Progressing Or Recurring After One Prior Chemotherapy
Conditions
Interventions
Sunitinib
Locations
18
China
Pfizer Investigational Site
Nanjing, Jiangsu, China
Pfizer Investigational Site
Beijing, China
Pfizer Investigational Site
Beijing, China
Pfizer Investigational Site
Guangzhou, China
Pfizer Investigational Site
Hong Kong, Hong Kong
Pfizer Investigational Site
Shatin, Hong Kong
Start Date
January 1, 2006
Primary Completion Date
May 1, 2008
Completion Date
May 1, 2008
Last Updated
March 30, 2015
NCT06885697
NCT06630130
NCT07035587
NCT01649271
NCT02310230
NCT06260150
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions